ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/4898892_CN98892_0